期刊文献+

厄多司坦祛痰作用的疗效观察 被引量:7

Expectorant effect of erdosteine
下载PDF
导出
摘要 目的观察国产厄多司坦祛痰作用的疗效。方法 78例患者随机分为治疗组(n=40)和对照组(n=38),治疗组口服国产厄多司坦胶囊300 mg,一日2次;对照组口服溴已新片16 mg,一日3次。疗程均为7天。结果治疗组和对照组的临床总有效率分别为67.5%和57.9%,两组对比差异无统计学意义(P>0.05);祛痰有效率分别为85.0%和63.1%,两组比较有显著性差异(P<0.05);不良反应发生率分别为5%和7.9%,两组对比无显著性差异(P>0.05)。结论国产厄多司坦胶囊用于祛痰治疗疗效和安全性与溴已新相当。 Objective To observe the expectorant effect of erdosteine made in China. Methods Seventy-eight patients were randomly divided into treatment group (n=40)and control group (n=38).The patients in treatment group were administrated with erdosteine capsules 300 mg orally twice a day, and the patients in control group were administrated with bromhexine hydrochloride tablets 16 mg orally three times a day for 7 days. Results The total effective rates of rates of treatment and control group were 67.5% and 57.9%, and there was no significant difference between two groups (P 〉0.05). The effective rates of expectorant of treatment and control group were 85.0% and 63.1% respectively, and there was significant difference between two groups (P〈0.05). The rates of adverse reaction were 5% and 7.9% respectively, and there was no significant difference between two groups (P〉0.05). Conclusion China made erdosteine capsule is as safe and effective as bromhexine hydrochloride for expectoration.
作者 陈利清
出处 《世界临床药物》 CAS 2011年第2期110-112,共3页 World Clinical Drug
关键词 厄多司坦 溴已新 祛痰作用 erdosteine bromhexine expectorant effect
  • 相关文献

参考文献3

二级参考文献28

  • 1[1]Inglesi M, Nicola M, Fregnan GB, et al. Synthesis and free radical scavenging properties of the enantiomers of erdosteine[J]. IL Farmaco, 1994,49(11)∶703-708.
  • 2[2]Barkenbus C, Landis PS. The preparation of thiazine [J]. J Am Chem Soc, 1948,70(2)∶684.
  • 3[3]Gonella J. [(2-Oxo-3-tetrahydrothienylcarbamoyl)-alkylthio] acetic acids, their salts and esters, a process for preparation thereof and the pharmaceutical compositions containing same[P]. EP:061386,FR:2502153,US:4411909,1983-10-25.(CA 1983,98∶71915m)
  • 4Fischer BM,Cuellar JG,Diehl ML,et al. [J]. Am J Respir Cell Mol Physiol, 2003,284 ( 4 ) :L671-679.
  • 5Lee I J, Hyun SW, Nandi A, et al. [ J ]. Am J Physiol Lung Cell Mol Physiol,2003,284 ( 1 ) : L160-168.
  • 6Buisine MP,Devisme L,Copin MC,et al. [J]. Am J Respir Cell Mol Biol,1999,20(2) :209-218.
  • 7Jackson AD. [J]. Trends Pharmacol Sci,2001,22( 1 ) :39-45.
  • 8Khawaja AM, Liu YC, Rogers DF, [ J ] Pulm Pharmacol Ther, 1999,12 (6) :363 -368.
  • 9Jaffe A, Rosenthal M. [ J]. Pediatr Pulmonol,2002,31 (6) :464-473.
  • 10Barnes PJ. [J]. Novartie Found Symp,2002,248:237 -249.

共引文献6

同被引文献34

  • 1强根荣,张晓忠,宋庆宝,单尚,范铮.N-(四氢-2-氧代-噻吩基)乙酰胺的合成[J].有机化学,2004,24(z1). 被引量:1
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8235
  • 3国家药典委员会.中国药典:二部[S].北京:中国医药科技出版社,2010:179-80.
  • 4朱应群.氨澳索对慢性阻塞性肺疾病患者气道炎症的影响.海南医学,2009,:234-235.
  • 5国家药典委员会.国家药品标准新药转正标准第62册[S].北京:人民卫生出版社,2008:171-172.
  • 6国家药典委员会.国家药品标准新药转正标准第58册[S].北京:人民卫生出版社,2005:144.
  • 7TSRL inc.Erdosteine[EB/OL] [2012-07-06].http://69.20.123.154/services/bcs/results.cfm.
  • 8刘慧,王本杰,袁桂艳,郭瑞臣.RP-HPLC法测定人血浆中厄多司坦浓度及其药代动力学研究[J].药物分析杂志,2007,27(10):1540-1543. 被引量:5
  • 9Bolser DC.Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest, 2006, 129 ( l Suppl) :238-249.
  • 10Moretti M, Bottrighi P, Dallari R, et al. The effect of long term treatment with erdoseteine on chronic obstructive pulmonary disease: The EQUALIFE study. Drugs Exp Clin Res, 2004, 30 (4) : 143-152.

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部